256 related articles for article (PubMed ID: 22706781)
1. Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?
Bourgier C; Levy A; Vozenin MC; Deutsch E
Cancer Metastasis Rev; 2012 Dec; 31(3-4):699-712. PubMed ID: 22706781
[TBL] [Abstract][Full Text] [Related]
2. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic approaches to radiation protection.
Brizel DM
J Clin Oncol; 2007 Sep; 25(26):4084-9. PubMed ID: 17827457
[TBL] [Abstract][Full Text] [Related]
4. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.
Bentzen SM
Nat Rev Cancer; 2006 Sep; 6(9):702-13. PubMed ID: 16929324
[TBL] [Abstract][Full Text] [Related]
5. Amelioration of the pathological changes induced by radiotherapy in normal tissues.
Rezvani M
J Pharm Pharmacol; 2008 Aug; 60(8):1037-48. PubMed ID: 18644196
[TBL] [Abstract][Full Text] [Related]
6. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins.
Lee TK; Stupans I
J Pharm Pharmacol; 2002 Nov; 54(11):1435-45. PubMed ID: 12495545
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
8. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
9. Research progress in the radioprotective effect of superoxide dismutase.
Huang XJ; Song CX; Zhong CQ; Wang FS
Drug Discov Ther; 2012 Aug; 6(4):169-77. PubMed ID: 23006987
[TBL] [Abstract][Full Text] [Related]
10. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
11. Radioprotectors and mitigators of radiation-induced normal tissue injury.
Citrin D; Cotrim AP; Hyodo F; Baum BJ; Krishna MC; Mitchell JB
Oncologist; 2010; 15(4):360-71. PubMed ID: 20413641
[TBL] [Abstract][Full Text] [Related]
12. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
13. Radioprotectors - the evergreen topic.
Kuntić VS; Stanković MB; Vujić ZB; Brborić JS; Uskoković-Marković SM
Chem Biodivers; 2013 Oct; 10(10):1791-803. PubMed ID: 24130023
[TBL] [Abstract][Full Text] [Related]
14. Radiation Protection and Mitigation by Natural Antioxidants and Flavonoids: Implications to Radiotherapy and Radiation Disasters.
Yahyapour R; Shabeeb D; Cheki M; Musa AE; Farhood B; Rezaeyan A; Amini P; Fallah H; Najafi M
Curr Mol Pharmacol; 2018; 11(4):285-304. PubMed ID: 29921213
[TBL] [Abstract][Full Text] [Related]
15. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
16. Radioprotective agents for radiation therapy: future trends.
Johnke RM; Sattler JA; Allison RR
Future Oncol; 2014 Dec; 10(15):2345-57. PubMed ID: 25525844
[TBL] [Abstract][Full Text] [Related]
17. Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
Fritz G; Henninger C; Huelsenbeck J
Br Med Bull; 2011; 97():17-26. PubMed ID: 21252099
[TBL] [Abstract][Full Text] [Related]
18. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization.
Farhood B; Goradel NH; Mortezaee K; Khanlarkhani N; Salehi E; Nashtaei MS; Mirtavoos-Mahyari H; Motevaseli E; Shabeeb D; Musa AE; Najafi M
Clin Transl Oncol; 2019 Mar; 21(3):268-279. PubMed ID: 30136132
[TBL] [Abstract][Full Text] [Related]
19. Amifostine: the first selective-target and broad-spectrum radioprotector.
Kouvaris JR; Kouloulias VE; Vlahos LJ
Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
[TBL] [Abstract][Full Text] [Related]
20. Radiation-induced toxicities: the role of radioprotectants.
Curran WJ
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):2-4. PubMed ID: 9794993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
